Sirion

There is no public evidence that Sirion is actively deploying capital. No filings with the SEC or state securities regulators, no press releases, no transaction records, and no professional profiles linked to the firm have been identified. Until a principal or transaction surfaces, the entity's operational status cannot be confirmed.

The most plausible explanations are that the firm has not yet commenced active investing, operates entirely below institutional reporting thresholds, or functions as a non-investment vehicle such as a holding company or administrative entity. Lehi's business-friendly environment could also indicate a registration of convenience without ongoing operations.

Yes. SirionLabs is a well-known enterprise contract lifecycle management software company, and Sirion Biotech is a recognized gene therapy player. Neither is related to this Lehi-based investment entity. Allocators should ensure they are evaluating the correct organization.

Due diligence on Sirion would be impossible using public sources alone. An allocator would need direct outreach—if a suitable contact could be identified—before any assessment of investment capability, compliance infrastructure, or track record could begin.

No ADV filings, Blue Sky notices, or state registration records have been located for a firm matching this name and location. This absence is significant, as even most exempt reporting advisers and smaller managers maintain some form of regulatory footprint.